Back to Search
Start Over
Evidence for Distinguishable Treatment Costs among Paranoid Schizophrenia and Schizoaffective Disorder.
- Source :
-
PloS one [PLoS One] 2016 Jul 08; Vol. 11 (7), pp. e0157635. Date of Electronic Publication: 2016 Jul 08 (Print Publication: 2016). - Publication Year :
- 2016
-
Abstract
- Background: Schizophrenia spectrum disorders result in enormous individual suffering and financial burden on patients and on society. In Germany, there are about 1,000,000 individuals suffering from schizophrenia (SZ) or schizoaffective disorder (SAD), a combination of psychotic and affective symptoms. Given the heterogeneous nature of these syndromes, one may assume that there is a difference in treatment costs among patients with paranoid SZ and SAD. However, the current the national system of cost accounting in psychiatry and psychosomatics in Germany assesses all schizophrenia spectrum disorders within one category.<br />Methods: The study comprised a retrospective audit of data from 118 patients diagnosed with paranoid SZ (F20.0) and 71 patients with SAD (F25). We used the mean total costs as well as partial cost, i.e., mean costs for medication products, mean personal costs and mean infrastructure costs from each patient for the statistical analysis. We tested for differences in the four variables between SZ and SAD patients using ANCOVA and confirmed the results with bootstrapping.<br />Results: SAD patients had a longer duration of stay than patients with SZ (p = .02). Mean total costs were significantly higher for SAD patients (p = .023). Further, we found a significant difference in mean personnel costs (p = .02) between patients with SZ and SAD. However, we found no significant differences in mean pharmaceutical costs (p = .12) but a marginal difference of mean infrastructure costs (p = .05) between SZ and SAD. We found neither a common decrease of costs over time nor a differential decrease in SZ and SAD.<br />Conclusion: We found evidence for a difference of case related costs of inpatient treatments for paranoid SZ and SAD. The differences in mean total costs seem to be primarily related to the mean personnel costs in patients with paranoid SZ and SAD rather than mean pharmaceutical costs, possibly due to higher personnel effort and infrastructure.
- Subjects :
- Adolescent
Adult
Aged
Aged, 80 and over
Cohort Studies
Electronic Health Records
Female
Germany
Humans
Male
Mental Health Services economics
Middle Aged
Psychiatry economics
Psychophysiologic Disorders economics
Retrospective Studies
Young Adult
Health Care Costs
Psychotic Disorders economics
Psychotic Disorders therapy
Schizophrenia, Paranoid economics
Schizophrenia, Paranoid therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1932-6203
- Volume :
- 11
- Issue :
- 7
- Database :
- MEDLINE
- Journal :
- PloS one
- Publication Type :
- Academic Journal
- Accession number :
- 27391238
- Full Text :
- https://doi.org/10.1371/journal.pone.0157635